MB
INZY

MPM BioImpact’s Inozyme Pharma INZY Stock Holding History

MPM BioImpact’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-323,813
Closed -$1.38M – 40
2023
Q4 		$1.38M Sell
323,813
-3,108
-1% -$11K 0.32% 31
2023
Q3 		$1.37M Hold
326,921
– – 0.37% 31
2023
Q2 		$1.82M Buy
326,921
+93,193
+40% +$551K 0.37% 32
2023
Q1 		$1.34M Buy
233,728
+3,228
+1% +$8.53K 0.35% 28
2022
Q4 		$242K Sell
230,500
-430,644
-65% -$753K 0.06% 33
2022
Q3 		$1.77M Sell
661,144
-3,836
-0.6% -$13.9K 0.42% 34
2022
Q2 		$3.17M Buy
664,980
+370,000
+125% +$1.61M 0.88% 26
2022
Q1 		$1.21M Sell
294,980
-7,635
-3% -$44.9K 0.32% 35
2021
Q4 		$2.06M Sell
302,615
-18,109
-6% -$156K 0.38% 32
2021
Q3 		$3.72M Buy
+320,724
New +$5M 0.58% 31

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MPM BioImpact's INZY Position: Q1 2024 in Review

MPM BioImpact sold out of Inozyme Pharma (INZY) in Q1 2024, closing a stake of 323,813 shares — an estimated $1.38M sold.

MPM BioImpact first reported a position in INZY in Q3 2021 and held it in 10 quarters. The position peaked at $3.72M in Q3 2021. 89 funds tracked by Wall St. Rank hold INZY as of Q1 2024.

  • MPM BioImpact reported no remaining Inozyme Pharma position as of Q1 2024 after selling out during the quarter.
  • MPM BioImpact sold 323,813 Inozyme Pharma shares in Q1 2024, an estimated $1.38M.
  • MPM BioImpact first reported a position in Inozyme Pharma in Q3 2021 and held it in 10 quarters.
  • MPM BioImpact's Inozyme Pharma position peaked at $3.72M in Q3 2021.
  • 89 funds tracked by Wall St. Rank held Inozyme Pharma as of Q1 2024.

Based on MPM BioImpact's 13F filing for Q1 2024, filed 15 May 2024.